Compare TEVA & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEVA | A |
|---|---|---|
| Founded | 1901 | 1999 |
| Country | Israel | United States |
| Employees | 32842 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5B | 39.8B |
| IPO Year | N/A | 1999 |
| Metric | TEVA | A |
|---|---|---|
| Price | $36.35 | $118.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | $38.63 | ★ $161.47 |
| AVG Volume (30 Days) | ★ 5.6M | 1.5M |
| Earning Date | 04-29-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 0.92% |
| EPS Growth | N/A | ★ 3.16 |
| EPS | N/A | ★ 1.07 |
| Revenue | N/A | ★ $4,472,000,000.00 |
| Revenue This Year | N/A | $8.45 |
| Revenue Next Year | $2.97 | $6.13 |
| P/E Ratio | ★ $28.19 | $109.82 |
| Revenue Growth | N/A | ★ 6.43 |
| 52 Week Low | $14.99 | $106.55 |
| 52 Week High | $37.35 | $160.27 |
| Indicator | TEVA | A |
|---|---|---|
| Relative Strength Index (RSI) | 74.07 | 53.49 |
| Support Level | $30.53 | $115.76 |
| Resistance Level | $37.35 | $130.54 |
| Average True Range (ATR) | 1.00 | 3.32 |
| MACD | 0.51 | 0.01 |
| Stochastic Oscillator | 97.85 | 54.75 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.